Keros Therapeutics (KROS)’s Takeda Pharmaceutical Milestone for Billion-Dollar Opportunity

This article explores whether Keros Therapeutics (KROS)'s $20 million milestone from Takeda Pharmaceutical Company Limited (TAK) could unlock a billion-dollar opportunity for the company.